Sequential Release of Pooled siRNAs and Paclitaxel by Aptamer-Functionalized Shell–Core Nanoparticles to Overcome Paclitaxel Resistance of Prostate Cancer

2021 ◽  
Author(s):  
Qianqian Guo ◽  
Yang Dong ◽  
Yanhua Zhang ◽  
Hao Fu ◽  
Chuanrong Chen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Paclitaxel Resistance ◽  
Sequential Release ◽  
Core Nanoparticles

scholarly journals The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines

The Prostate ◽  
2007 ◽  
Vol 67 (9) ◽  
pp. 955-967 ◽  
Author(s):  
Masashi Takeda ◽  
Atsushi Mizokami ◽  
Kiminori Mamiya ◽  
You Qiang Li ◽  
Jian Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cancer Cell Lines ◽  
Paclitaxel Resistance ◽  
Prostate Cancer Cell Lines

MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms

The Prostate ◽  
2010 ◽  
Vol 70 (14) ◽  
pp. 1501-1512 ◽  
Author(s):  
Keitaro Kojima ◽  
Yasunori Fujita ◽  
Yoshinori Nozawa ◽  
Takashi Deguchi ◽  
Masafumi Ito
Keyword(s):  
Prostate Cancer ◽  
Hormone Refractory Prostate Cancer ◽  
Paclitaxel Resistance ◽  
Pc3 Cells ◽  
Hormone Refractory

MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1

2017 ◽  
Vol 36 (3) ◽  
pp. 357-365 ◽  
Author(s):  
Lei Chen ◽  
Hongwen Cao ◽  
Yigeng Feng
Keyword(s):  
Prostate Cancer ◽  
Paclitaxel Resistance

scholarly journals Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer

2013 ◽  
Vol 114 (6) ◽  
pp. 1286-1293 ◽  
Author(s):  
John J. Kim ◽  
Bo Yin ◽  
Christhunesa S. Christudass ◽  
Naoki Terada ◽  
Krithika Rajagopalan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Paclitaxel Resistance ◽  
Invasive Phenotype

scholarly journals MiR-148a Attenuates Paclitaxel Resistance of Hormone-refractory, Drug-resistant Prostate Cancer PC3 Cells by Regulating MSK1 Expression

2010 ◽  
Vol 285 (25) ◽  
pp. 19076-19084 ◽  
Author(s):  
Yasunori Fujita ◽  
Keitaro Kojima ◽  
Riyako Ohhashi ◽  
Nanako Hamada ◽  
Yoshinori Nozawa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Resistant ◽  
Paclitaxel Resistance ◽  
Pc3 Cells ◽  
Hormone Refractory

scholarly journals Downregulation of cytokeratin 18 is associated with paclitaxel-resistance and tumor aggressiveness in prostate cancer

2016 ◽  
Vol 48 (4) ◽  
pp. 1730-1736 ◽  
Author(s):  
BO YIN ◽  
MO ZHANG ◽  
YU ZENG ◽  
YOUQIANG LI ◽  
CHAO ZHANG ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Aggressiveness ◽  
Paclitaxel Resistance ◽  
Cytokeratin 18

scholarly journals Chemosensitizing effects of methyl jasmonate on paclitaxel-resistant androgen-dependent and independent prostate cancer cell lines

Genetika ◽  
2021 ◽  
Vol 53 (1) ◽  
pp. 131-140
Author(s):  
Seda Orenay-Boyacioglu ◽  
Olcay Boyacioglu
Keyword(s):  
Prostate Cancer ◽  
Methyl Jasmonate ◽  
Cell Lines ◽  
Resistant Cell ◽  
Cancer Drug ◽  
Paclitaxel Resistance ◽  
Innovative Strategies ◽  
Average Survival ◽  
22Rv1 Cell ◽  
Luminescent Assay

The taxane-based therapy provides survival benefit in patients with metastatic prostate cancer; however, the average survival is less than 20 months due to the partial taxane-related chemoresistance. Innovative strategies are needed to overcome the chemoresistance for improved patient survival. In this project, paclitaxel-resistance was developed on androgen-independent PC3 and androgen-dependent 22Rv1 and LNCaP human prostate cancer (PCa) cell lines to investigate the efficacy of methyl jasmonate (MeJa), an anti-cancer drug, in overcoming the chemoresistance. The PCa cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37?C under 5% CO2. The cell lines were exposed to the gradually increasing doses of paclitaxel. Since the resistance on LNCaP could not be achieved, the study was continued with 22Rv1 cell line. It was demonstrated that paclitaxel-resistant cell lines overexpress ABCB1. Resistance levels of cells and MeJa activity in all resistant and parental lines were measured using CellTiter-Glo? luminescent assay. Test results were compared with Student?s t-test or analysis of variance (ANOVA). P?0.05 (two-tailed) was considered to be significant. In conclusion, MeJa showed more cytotoxicity on paclitaxel resistant PC3 (PC3-PtxR) cells than resistant 22Rv1 (22Rv1-PtxR) cells. Detection of cytotoxic effects of MeJa in overcoming paclitaxel resistance may contribute to the development of alternative new compounds for the prevention or chemosensitization of resistance to chemotherapeutics such as paclitaxel.

scholarly journals Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer

2015 ◽  
Vol 20 (5-6) ◽  
pp. 407-417 ◽  
Author(s):  
Justin Q. Wang ◽  
Austin DeChalus ◽  
Devin N. Chatterjee ◽  
Evan T. Keller ◽  
Atsushi Mizokami ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Extracellular Vesicle ◽  
Paclitaxel Resistance
Sign in / Sign up

Export Citation Format

Share Document